News & Media

About Asieris Pharmaceuticals

Asieris Pharmaceuticals is committed to leading the development of new drugs for the treatment of genitourinary tumors and other diseases. Together we improve human health to make life more dignified. 

APL-1702 (Cevira®)

APL-1702 (Cevira®) is a photodynamic drug-device combination product. It is developed for the treatment of cervical high grade squamous intraepithelial lesion (HSIL) caused by infection with all HPV subtypes.

Bladder Cancer Primer

Bladder cancer is a fast-growing major disease around the world with unmet treatments needs. 

Asieris Logo
Asieris Office